Association between IGF-1 levels and MDD: a case-control and meta-analysis

Area of Science:

• Neuroscience
• Endocrinology
• Psychiatry

Background:

• Insulin-like Growth Factor-1 (IGF-1) possesses neurotrophic properties, influencing neurogenesis, remyelination, and synaptogenesis.
• IGF-1 is recognized as a regulator of neuronal plasticity.
• While IGF-1's role in depression is studied, research on first-episode, drug-naïve patients is limited.

Purpose of the Study:

• To investigate serum IGF-1 levels in patients experiencing their first episode of depression without prior antidepressant use.
• To compare IGF-1 levels between first-episode, drug-naïve depression patients and matched healthy controls.
• To supplement existing evidence on IGF-1 in depressive disorders.

Main Methods:

• A case-control study involving 60 first-episode, drug-naïve depression patients and 60 matched healthy controls.
• Serum IGF-1 levels were compared between the depression group and the control group.
• A meta-analysis of 13 existing case-control studies was conducted to validate findings.

Main Results:

• Serum IGF-1 levels were significantly higher in first-episode, drug-naïve depression patients compared to healthy controls (p<0.05).
• No significant differences in IGF-1 levels were observed between genders within the depressed group.
• No significant correlations were found between serum IGF-1 levels and age or depression severity.

Conclusions:

• First-episode, drug-naïve depression is associated with elevated serum IGF-1 levels.
• Careful exclusion of confounding factors is crucial in studies examining IGF-1 in depression.
• Further research is warranted to elucidate the precise role of IGF-1 in depression.